The MARC Animal Core will serve the Center by purchasing, testing, breeding, maintaining and distributing animals to MARC investigators. The Animal Core will serve five major purposes: (1) Purchase and set up breeders to produce animals for the MARC Scientific Components;(2) Behaviorally test mice associated with the creation of short-term selection lines to be used by Scientific Components 5 and 6 (3) Determine animal distribution priorities and develop distribution procedures;(4) Develop new behavioral testing procedures and obtain animals on an as needed basis for new pilot projects or changes in direction as they occur;(5) Maintain a database that will track individual animals and post trait data for all MARC investigators to view and utilize. F1 or F2 mice that are the descendents of C57BL/6J (B6) and DBA/2J (D2) inbred strain mice will be used in Scientific Components 5 and 6, and Pilot Project 8B. The Core will breed F1 and F2 mice for use in these components. A set of replicated mouse lines selected for high and low methamphetamine (MA) drinking, and an independent set for high and low MA-induced sensitization will be created within the Animal Core for distribution to Scientific Components 5 and 6. B6 breeders will also be set up to produce the neonates to be treated in the Core for Pilot Project 8C. The Animal Core will be managed by Dr. John Crabbe, who is experienced in developing animal models of addiction, and will be capable of providing other strains or genotypes of mice for new pilots on an as needed basis. All animals will be housed in AALAC accredited animal facilities under the full-time supervision of a licensed veterinarian. Procedures are in place for the avoidance of viral and bacterial contamination, and a sentinel screening program is used to quickly identify contamination and avoid spread. Careful genetic record-keeping and identification practices for the maintenance of a large number of genotypes have been in place for several years. Key advantages of the Animal Core are cost savings associated with centralized development, behavioral testing and distribution of the selected line mice;controlled environmental conditions;genetic quality control; removal of animal production burden from Component Pis. Decisions about animal distribution will be centralized and based on a number of criteria, including date of request, whether the request is for a MARC project, scientific progress, and date of last distribution to that project. The Core will be able to distribute littermates across projects to minimize litter effects within studies, and increase the potential for crossexperiment association analyses. Core practices will strengthen the data generated by the MARC.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZDA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oregon Health and Science University
United States
Zip Code
Shabani, Shkelzen; Schmidt, Bryan; Ghimire, Bikalpa et al. (2018) Depression-like symptoms of withdrawal in a genetic mouse model of binge methamphetamine intake. Genes Brain Behav :e12533
Eshleman, Amy J; Nagarajan, Shanthi; Wolfrum, Katherine M et al. (2018) Structure-activity relationships of bath salt components: substituted cathinones and benzofurans at biogenic amine transporters. Psychopharmacology (Berl) :
McCready, Holly; Kohno, Milky; Kolessar, Michael et al. (2018) Functional MRI and delay discounting in patients infected with hepatitis C. J Neurovirol 24:738-751
Loftis, Jennifer M; Valerio, Juno; Taylor, Jonathan et al. (2018) S100B and Inflammatory Cytokine Levels in Blood as Potential Markers of Blood-Brain Barrier Damage and Psychiatric Impairment in Comorbid Hepatitis C Viral Infection and Alcohol Use Disorder. Alcohol Clin Exp Res :
Eshleman, Amy J; Wolfrum, Katherine M; Reed, John F et al. (2018) Neurochemical pharmacology of psychoactive substituted N-benzylphenethylamines: High potency agonists at 5-HT2A receptors. Biochem Pharmacol 158:27-34
Tosh, Dilip K; Ciancetta, Antonella; Mannes, Philip et al. (2018) Repurposing of a Nucleoside Scaffold from Adenosine Receptor Agonists to Opioid Receptor Antagonists. ACS Omega 3:12658-12678
McCarty, Dennis; Priest, Kelsey C; Korthuis, P Todd (2018) Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. Annu Rev Public Health 39:525-541
Eastwood, Emily C; Eshleman, Amy J; Janowsky, Aaron et al. (2018) Verification of a genetic locus for methamphetamine intake and the impact of morphine. Mamm Genome 29:260-272
Kohno, Milky; Dennis, Laura E; McCready, Holly et al. (2018) A preliminary randomized clinical trial of naltrexone reduces striatal resting state functional connectivity in people with methamphetamine use disorder. Drug Alcohol Depend 192:186-192
Holton, Dwight; White, Elizabeth; McCarty, Dennis (2018) Public Health Policy Strategies to Address the Opioid Epidemic. Clin Pharmacol Ther 103:959-962

Showing the most recent 10 out of 143 publications